TSE:4502Pharmaceuticals
Should FDA Approval of ORZEYFUL for Narcolepsy Type 1 Prompt Action From Takeda Pharmaceutical (TSE:4502) Investors?
On 5 August 2026, Takeda Pharmaceutical announced that the U.S. FDA approved ORZEYFUL (oveporexton), a first-in-class oral orexin receptor 2 agonist, for treating narcolepsy type 1 with cataplexy in adults, with commercial launch pending DEA controlled substance scheduling.
This approval gives Takeda a differentiated entry into a rare disease market of an estimated 120,000 U.S. patients, addressing the underlying orexin deficiency rather than only individual narcolepsy symptoms.
We will now...